why choose us

First received: September 07, 2022

Clinical Trial: Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Geographic Atrophy

Study Type: INTERVENTIONAL


Official Title: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Compl

Brief Summary: The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

Read more